Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $17.25.

A number of analysts have recently issued reports on FOLD shares. JPMorgan Chase & Co. lowered their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Finally, Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target on the stock.

Amicus Therapeutics Stock Up 0.2 %

Shares of NASDAQ FOLD opened at $11.27 on Thursday. The firm has a market cap of $3.34 billion, a price-to-earnings ratio of -23.00 and a beta of 0.69. The company’s 50-day simple moving average is $10.91 and its 200-day simple moving average is $10.82. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics has a 52-week low of $9.02 and a 52-week high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. During the same period last year, the company posted ($0.15) EPS. Amicus Therapeutics’s quarterly revenue was up 34.0% compared to the same quarter last year. Equities analysts predict that Amicus Therapeutics will post -0.08 EPS for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Bradley L. Campbell sold 6,100 shares of the stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $10.34, for a total value of $77,550.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,100 shares of company stock worth $226,375. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Headlands Technologies LLC acquired a new position in shares of Amicus Therapeutics in the 2nd quarter worth approximately $89,000. Sage Capital Advisors llc acquired a new position in Amicus Therapeutics during the second quarter worth $103,000. Old Well Partners LLC purchased a new position in shares of Amicus Therapeutics during the fourth quarter worth $180,000. EntryPoint Capital LLC grew its stake in shares of Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 9,729 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at $138,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.